Business
Cabaletta Bio is a late clinical-stage biotechnology company developing engineered T cell therapies for autoimmune diseases.
Cabaletta's FY2025 loss and cash burn widened, but cluster insider buying appeared as rese-cel moved into a registrational trial.
The read at a glance✓ Audited against SEC data
- Business mix — Autoimmune cell therapyNote
- Lead asset — Rese-celNote
- Net loss — $167.9M lossWatch
- FCF — -$132.3MWatch
- Equity — $112.1M, -26.4%Watch
- Insiders — 8 purchases / 0 salesOK
- Accounting — Forensic screen unavailableNote
Leadership changes
From Cabaletta Bio, Inc.'s own filings, the day they're filed.
- Shawn Tomasello · Directors · appointmenteff. 2023-07-21
- Eligible Participant · departure
- Catherine Bollard · departure
Latest filings
- 8-K · Company announcement2026-08-13
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-06-11
- 8-K · Company announcement2026-06-03
- 10-Q · Quarterly report2026-05-14
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Cabaletta Bio, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.